<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-883-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SOLIAN 400 MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMISULPRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        220.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Dijon" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Dijon
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AL08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: Antipsychotics, ATC code: N05AL05 Solian belongs to a group of medicines known as antipsychotics.<br />This medicine is used to treat people with schizophrenia. Schizophrenia is a mental illness characterised by various mental and behavioural disorders, such as hallucinations or agitation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Solian 400 mg scored film-coated tablets:<br />&bull; if you are allergic to the active substance (amisulpride) or any of the other ingredients of this medicine (listed in section 6)<br />&bull; if you have a pheochromocytoma (excessive growth of the adrenal glands around the kidneys, releasing substances which cause high blood pressure)<br />&bull; in children under 15 years of age<br />&bull; if you have a prolactin-dependent tumour (prolactin is a hormone that stimulates milk production), e.g. breast cancer or pituitary disorders<br />&bull; if you are taking other medicines. If this is the case, make sure that combined use with Solian is not contraindicated (see &ldquo;Other medicines and Solian&rdquo;).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Solian 400 mg scored film-coated tablets.<br />Your doctor may ask you to have an electrocardiogram (ECG) before starting treatment. This medicine can cause heart rhythm disorders (see section 4).<br />This medicine should be used with caution in the following situations:<br />&bull; in elderly patients, particularly if they have dementia, because of the risk of a drop in blood pressure and of drowsiness; if the patients have kidney failure your doctor may reduce the dose<br />&bull; if you have risk factors for stroke, which occurs when the blood flow is abruptly interrupted in part of the brain</p><p>if you or a family member have a history of blood clots, since taking antipsychotic drugs may cause<br />FST10 full - PDTAUT_FOR011 v06<br />blood clots to form<br />&bull; if you have kidney disease (kidney failure), in which case your doctor may reduce the dose<br />&bull; if you have epilepsy or Parkinson&#39;s disease<br />&bull; if you have diabetes or if you have risk factors for diabetes<br />&bull; if you have a history of hyperprolactinemia (too much prolactin in the blood) or a prolactin-dependent tumour (prolactin is a hormone that stimulates milk production), e.g. breast cancer or pituitary disorders. If this is the case, your doctor will have to monitor you closely during treatment.<br />Serious liver problems have been reported with Solian 400 mg scored film-coated tablets. Tell your doctor immediately if you experience tiredness, loss of appetite, nausea, vomiting, abdominal pain or yellowing of the eyes or skin.<br />If, during treatment, you develop muscle stiffness and consciousness disorders, along with an unexplained fever, stop treatment immediately and contact your doctor straight away.<br />If, during treatment, you develop visual disturbances or headaches, consult your doctor quickly.<br />If you develop an infection or unexplained fever, your doctor may have you undergo a blood test immediately. This is because this medicine may have an effect on your blood cells, i.e. reduce the number of white blood cells. This problem can be seen in a blood test (see section 4, &ldquo;Possible side effects&rdquo;).<br />Treatment with this medicine should not be suddenly stopped because this can cause a withdrawal syndrome. This is characterised by signs such as insomnia, nausea and vomiting. Abnormal movements may also be observed, and psychotic disorders recur.<br />Children and adolescents<br />&bull; This medicine should not be given to children under 15 years of age<br />&bull; Use of this medicine is not recommended in children between 15 and 18 years of age.<br />Other medicines and Solian 400 mg scored film-coated tablets<br />Tell your doctor or pharmacist if you are taking, have recently taken or may take any other medicines.<br />You must not take this medicine with cabergoline, quinagolide (medicines used to treat milk production disorders), citalopram or escitalopram (medicines used to treat anxiety or depression), domperidone (medicine used to treat nausea and vomiting), hydroxyzine (medicine used to treat anxiety or hives) or piperaquine (medicine used to treat malaria).<br />You must avoid taking this medicine with:<br />&bull; some medicines used to treat Parkinson&#39;s disease (amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramipexole, rasagiline, ropinirole, rotigotine, selegiline, tolcapone)<br />&bull; levodopa<br />&bull; sodium oxybate (medicine used to treat narcolepsy)<br />&bull; some medicines which may cause serious heart rhythm disorders (called &ldquo;torsades de pointes&rdquo;) such as:<br />o medicines used to treat irregular heartbeat (class Ia antiarrhythmics such as quinidine, hydroquinidine, disopyramide and class III antiarrhythmics such as amiodarone, dronedarone, sotalol, dofetilide and ibutilide)<br />o some medicines used to treat psychiatric disorders (chlorpromazine, cyamemazine, droperidol, flupenthixol, fluphenazine, haloperidol, levomepromazine, pimozide, pipamperone, pipotiazine, sulpiride, sultopride, tiapride, zuclopenthixol)<br />o some antiparasitic agents (chloroquine, halofantrine, lumefantrine, pentamidine)<br />o a medicine used to treat dependence on some drugs (methadone)<br />o other medicines such as: arsenic compounds, diphemanil, dolasetron IV, erythromycin IV, hydroxychloroquine, levofloxacin, mequitazine, mizolastine, prucalopride, vincamine IV, moxifloxacin, spiramycin IV, toremifene, vandetanib<br />&bull; medicines containing alcohol.<br />Solian 400 mg scored film-coated tablets with food, drink and alcohol<br />As with all antipsychotic drugs in this group, you must avoid drinking alcoholic beverages during treatment.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<br />FST10 full - PDTAUT_FOR011 v06<br />Pregnancy<br />Solian 400 mg scored film-coated tablets are not recommended during pregnancy or in women of childbearing potential who are not using effective contraception.<br />If you use Solian 400 mg scored film-coated tablets during the last 3 months of your pregnancy, your baby may experience agitation, increased muscle stiffness, involuntary trembling, drowsiness, breathing problems or difficulty feeding or suckling.<br />If your baby has any of these symptoms, contact your doctor quickly. Breast-feeding<br />You must not breast-feed during treatment with Solian 400 mg scored film-coated tablets. Ask your doctor about the best way to feed your baby if you are taking Solian 400 mg scored film-coated tablets.<br />Driving and using machines<br />This medicine can cause drowsiness and blurred vision. You must take care if you drive a vehicle or use machines.<br />Solian 400 mg scored film-coated tablets contain lactose<br />This medicine contains a type of sugar (lactose) that is broken down into galactose and glucose. You should not use this medicine if you have galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption syndrome (rare hereditary diseases).<br />If your doctor has told you that you have an intolerance to certain sugars, contact him/her before taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />Do not stop the treatment of your own accord.<br />This medicine should be taken by mouth.<br />Swallow the tablet(s) with a small amount of water.<br />If you take more Solian 400 mg scored film-coated tablets than you should:<br />You may experience drowsiness, sedation (a relaxing effect), a drop in blood pressure, extrapyramidal symptoms (particularly trembling and muscle stiffness) or you may fall into a coma.<br />If any of these occur, it is absolutely essential that you or your family/friends call a doctor or the emergency medical services.<br />If you forget to take Solian 400 mg scored film-coated tablets:<br />Do not take a double dose to make up for a forgotten dose. Take the following dose at the usual time.<br />If you have forgotten several doses, ask your doctor for advice.<br />If you stop taking Solian 400 mg scored film-coated tablets:<br />Not applicable.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If, during treatment, you develop muscle stiffness and consciousness disorders, along with an unexplained fever, stop treatment immediately and seek urgent medical attention.<br />The following side effects are very common (affecting more than 1 patient in 10):<br />&bull; trembling, muscle stiffness, cramps, abnormal movements, producing more saliva than usual.<br />The following side effects are common (affecting 1 to 10 patients in 100):<br />&bull; stiff neck, oculogyric crises (abnormal movement of certain eye muscles), intense contraction of jaws &bull; drowsiness<br />&bull; insomnia, anxiety, agitation<br />&bull; constipation, nausea, vomiting, dry mouth<br />FST10 full - PDTAUT_FOR011 v06<br />&bull; frigidity (lack of sexual pleasure in women)<br />&bull; hyperprolactinemia (too much prolactin, the hormone that induces milk production, in the blood), which may cause: o in women: absence of menstrual periods, abnormal production of breast milk, breast pain o in men: swelling of breasts, impotence (erection difficulties)<br />&bull; weight gain<br />&bull; low blood pressure (hypotension)<br />&bull; blurred vision.<br />The following side effects are uncommon (affecting 1 to 10 patients in 1 000):<br />&bull; involuntary movements of the tongue and/or face<br />&bull; seizures (involuntary contractions of one or more muscles)<br />&bull; hyperglycaemia (too much sugar in the blood)<br />&bull; hypertriglyceridemia (too much fat (triglycerides) in the blood)<br />&bull; hypercholesterolaemia (too much cholesterol in the blood)<br />&bull; slow heartbeat<br />&bull; increased levels of certain liver enzymes, mainly transaminases<br />&bull; liver tissue injury<br />&bull; reduced bone density or change in bone structure (osteopenia, osteoporosis), weakening the bones<br />&bull; allergic reactions<br />&bull; confusion<br />&bull; stuffy nose<br />&bull; lung disorders (aspiration pneumonia) that may appear as inflammation, difficulty breathing, an infection, cough (mainly in combination with other drugs with a central nervous depressant effect)<br />&bull; increase in blood pressure<br />&bull; difficulty urinating<br />&bull; leukopenia, neutropenia (see section 2, paragraph &ldquo;Warnings and precautions&rdquo;).<br />The following side effects are rare (affecting 1 to 10 patients in 10 000):<br />&bull; agranulocytosis (a low level of white blood cells) (see section 2 &ldquo;Warnings and precautions&rdquo;)<br />&bull; benign pituitary tumour, which may cause signs such as visual disturbances or headaches<br />&bull; drop in the amount of sodium in the blood (hyponatremia), syndrome of inappropriate antidiuretic hormone secretion<br />&bull; unexplained fever, along with general and neurological disorders<br />&bull; serious fainting (loss of consciousness), heart rhythm disorders possibly causing death (see section 2)<br />&bull; swelling, pain and redness of the legs. This is because blood clots in the veins (particularly in the legs) can move through blood vessels to reach the lungs, causing chest pain and difficulty breathing &bull; sudden swelling of the face and/or neck that can lead to difficulty breathing and may be life-threatening (angioedema), red, itchy patches on the skin (hives).<br />The following side effects may occur, but their frequency is not known:<br />&bull; withdrawal syndrome in newborn infants (see section 2 &ldquo;Pregnancy&rdquo;)<br />&bull; restless legs syndrome (uncomfortable feeling in the legs that is temporarily relieved by movement, and is worse at the end of the day)<br />&bull; increased skin sensitivity when exposed to sun and ultraviolet rays<br />&bull; falls due to loss of balance, which may involve fractures.<br />Reporting of side effects<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month.<br />FST10 full - PDTAUT_FOR011 v06<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is:<br />Amisulpride .............................................................................................................. 400 mg<br />For one scored film-coated tablet<br />&bull; The other ingredients are:<br />Sodium starch glycolate (Type A), lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate, white Sepifilm 752 (hypromellose, microcrystalline cellulose, polyoxyl 40 stearate, titanium dioxide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is available as scored tablets.
Box of 30, 80, 100 or 150 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />SANOFI-AVENTIS FRANCE<br />82 AVENUE RASPAIL<br />94250 GENTILLY, FRANCE<br /><br />Manufacturer<br />DELPHARM DIJON<br />6, BOULEVARD DE L&rsquo;EUROPE<br />21800 QUETIGNY, FRANCE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09-2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ینتمي سولیان إلى فئة من الأدویة تسُمّى مضادات الذھان.<br />یُستعمل ھذا الدواء لعلاج الأشخاص الذین یعانون من الفُصام. الفُصام مرض نفسي یتمیّز ببعض الاضطرابات النفسیّة<br />والسلوكیّة، مثلا ھلوسات أو ھیاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعمال<br />لا تأخذ سولیان:<br />&bull; إذا كنت تعاني من حساسیّة ضد المادة الفاعلة (أمیسولبرید) أو ضد أحد المكوّنات الأخرى التي یحتوي ھذا الدواء<br />. علیھا المذكورة في القسم 6<br />&bull; إذا كنت تعاني من ورم القواتم (نمو مفرط في الغدد الكظریّة الموجودة على مستوى الكلیتین والتي تفرز موادًا تسبّب<br />ارتفاعًا في ضغط الدم) ،<br />&bull; لدى الأطفال ما دون 15 عامًا.<br />&bull; إذا كان لدیك ورم متعلّق بالبرولاكتین (ھورمون إفراز الحلیب)، مثلاً سرطان الثدي أو اضطرابات تعود إلى الغدّة<br />النخامیةّ.<br />&bull; إذا كنت تأخذ دواء آخر، تأكّد من أنّ أخذه بالاشتراك مع سولیان غیر ممنوع (راجع فقرة &quot;أدویة أخرى وسولیان&quot;).<br />تحذیرات واحتیاطات<br />إستشر الطبیب أو الصیدليّ قبل أخذ سولیان.<br />یمكن أن یجُري لك طبیبك مخططًا لكھربائیّة القلب قبل أن یُعطیك ھذا العلاج. في الواقع، یمكن أن یسبّب ھذا الدواء<br />اضطرابات في النظم القلبي (راجع القسم 4<br />یجب استعمال ھذا الدواء بحذر في الحالات الآتیة:<br />&bull; لدى الأشخاص المسنّین، لا سیّما إذا كانوا مصابین بالعتھ، بسبب خطر انخفاض الضغط الشریاني والنعاس؛ في حالة<br />الفشل الكلوي، یمكن أن یخفضّ طبیبك مقدار الجرعة ،<br />&bull; إذا كان لدیك عوامل خطر الإصابة بسكتة دماغیّة (تُسمّى أیضًا &quot;جلطة&quot; وتحصل عندما تتوقّف الدورة الدمویّة فجأة<br />في قسم من الدماغ)،<br />&bull; إذا أُصبت أنت أو أحد من أفراد عائلتك سابقًا بتشكّل جلطات دمویّة لأنّ تناول مضادات الذھان یمكن أن یسبّب تشكّل<br />جلطات دمویةّ،<br />&bull; إذا كنت مصابًا بمرض كلويّ (فشل كلوي). في ھذه الحالة یمكن أن یخفّض طبیبك الجرعة،<br />&bull; إذا كنت تعاني من الصرع أو من داء باركنسون،<br />&bull; إذا كنت مصابًا بداء السكّري أو إذا كان لدیك عوامل خطر الإصابة بالسكّري.<br />&bull; إذا أصبت سابقاً بفرط برولاكتین الدم (كمیةّ مفرطة من البرولاكتین في الدم) أو بورم متعلقّ بالبرولاكتین (ھورمون<br />إفراز الحلیب)، مثلاً سرطان الثدي أو اضطرابات تعود إلى الغدّة النخامیّة. في ھذه الحالة، یجب أن یراقبك طبیبك<br />بدقةّ في خلال فترة العلاج.<br />أفید عن حصول مشاكل كبدیّة خطیرة مع سولیان. أعلم طبیبك على الفور إذا شعرت بالتعب أو بفقدان الشھیّة أو بالغثیان أو<br />بالتقیّؤ أو بأوجاع في البطن أو باصفرار في العینین أو البشرة.<br />في حال أصبت بتیبّس في العضلات وباضطرابات في الوعي مع حمى غیر مبررة في خلال فترة العلاج، یجب أن تتوقّف<br />فورًا عن استعمال الدواء واستشارة الطبیب في الحال.<br />في خلال فترة العلاج، إذا أصبت باضطرابات في الرؤیة أو بأوجاع في الرأس، استشر طبیبك على الفور.<br />في حالة الإصابة بعدوى أو بحمى غیر مبررة، یمكن أن یطلب منك طبیبك إجراء فحص دم على الفور. في الواقع یمكن أن<br />. یسببّ ھذا الدواء اختلالا في عناصر الدم (انخفاض عدد كریات الدم البیضاء) یظھر في نتائج فحص الدم (راجع القسم 4<br />&quot;ما ھي التأثیرات الجانبیةّ المحتملة&quot;).<br />لا ینبعي إیقاف ھذا الدواء بشكل مفاجئ لأنّ ذلك یمكن أن یسبّب ظھور ظاھرة الفطام التي تتمیزّ بظھور عوارض مثل<br />الأرق والغثیان والتقیؤّ ولكن یمكن أن تتمّ أیضًا ملاحظة حركات غیر طبیعیةّ وأن تظھر مجددّاً اضطرابات ذھانیةّ.<br />الأطفال والمراھقون<br />&bull; لا ینبغي استعمال ھذا الدواء لدى الأطفال ما دون الخامسة عشرة من العمر.<br />&bull; لا یُنصح باستعمال ھذا الدواء بین عمر الخامسة عشرة والثامنة عشرة.<br />أدویة أخرى وسولیان<br />أعلم الطبیب أو الصیدلي إذا كنت تأخذ حالیًا أو أخذت مؤخّرًا أو قد تأخذ أيّ دواء آخر.<br />لا ینبغي بك أبداً أخذ ھذا الدواء مع الكابرجولین والكیناغولید (دواءان یسُتعملان في اضطرابات الإرضاع) والسیتالوبرام<br />والإسكیتالوبرام (دواءان یسُتعملان لعلاج القلق أو الاكتئاب) والدومبیریدون (دواء یسُتعمل لعلاج الغثیان والتقیؤّ)<br />والھیدروكسیزین (دواء یسُتعمل لعلاج القلق أو الشّرى) والبیبیراكین (دواء یسُتعمل لعلاج الملاریا).<br />یجب علیك تفادي أخذ ھذا الدواء مع:<br />&bull; بعض الأدویة المستعملة في علاج داء باركنسون (أمانتادین، أبومورفین، بروموكریبتین، انتاكابون، لیزورید،<br />برغولید، بیریبیدیل، برامیبكسول، رازاجیلین، روبینیرول، روتیغوتین، سیلیجیلین، تولكابون)،<br />&bull; اللیفودوبا،<br />&bull; أوكسیبات الصودیوم (دواء یسُتعمل لعلاج الخدار) ،<br />بعض الأدویة التي یمكن أن تسببّ اضطرابات خطیرة في النظم القلبي (التواء أطراف البطینین بسبب كثرة خفقانھا)<br />مثل:<br />مثل كینیدین وھیدروكینیدین Ia - أدویة مستعملة لعلاج عدم انتظام ضربات القلب (مضادات اللانظمیةّ من الفئة<br />مثل أمیودارون ودرونیدارون وسوتالول ودوفیتیلید وإیبوتیلید)، III ودیزوبیرامید ومضادات اللانظمیةّ من الفئة<br />- بعض الأدویة المضادة للاضطرابات النفسیةّ (كلوربرومازین، سیامیمازین، دروبیریدول، فلوبنتیكسول،<br />فلوفینازین، ھالوبیریدول، لیفومیبرومازین، بیموزید، بیبامبیرون، بیبوتیازین، سولبیرید، سولتوبرید، تیابرید،<br />زوكلوبنتیكسول)،<br />- بعض مضادات الطفیلیاّت (كلوروكین، ھالوفانترین، لومیفانترین، بنتامیدین)،<br />- دواء یسُتعمل لمكافحة الإدمان على بعض المخدرّات (میتادون)،<br />ھیدروكسیكلوروكین، ،IV إیریثرومیسین ،IV - أدویة أخرى مثل: الزرنیخ، دیفیمانیل، دولازیترون<br />،IV موكسیفلوكساسین، سبیرامیسین ،IV لیفوفلوكساسین، میكیتازین، میزولاستین، بروكالوبرید، فینكامین<br />توریمیفین، فاندیتانیب،<br />&bull; أدویة تحتوي على الكحول.<br />سولیان مع الطعام والشراب والكحول<br />كما مع كل مضادات الذھان من فئة الأدویة ھذه، یجب علیك تفادي استھلاك المشروبات الكحولیّة في خلال فترة العلاج.<br />الحمل والإرضاع<br />إذا كنتِ حاملاً أو مرضعة أو إذا كنتِ تعتقدین نفسك حاملاً أو كنتِ تنوین الحمل، استشیري الطبیب قبل أخذ ھذا الدواء.<br />الحمل<br />لا یُنصح باستعمال ھذا الدواء في خلال فترة الحمل ولدى النساء في سنّ الإنجاب اللواتي لا یستعملن وسیلة منع حمل<br />فعّالة.<br />إذا أخذت سولیان في خلال الأشھر الثلاثة الأخیرة من حملك، یمكن أن تظھر العوارض الآتیة على طفلك: ھیاج، زیادة<br />التیبسّ العضلي، رجفة غیر إرادیّة في الجسم، نعاس، مشاكل في التنفسّ أو صعوبات في التغذیة/الرضاعة.<br />إذا عانى طفلك من أيّ من ھذه العوارض، اتصلي بالطبیب على الفور.<br />الإرضاع<br />لا ینبغي بكِ الإرضاع في خلال فترة العلاج بسولیان. إسألي الطبیب ما ھي الطریقة الفضلى لإطعام طفلك إذا كنتِ تأخذین<br />سولیان.<br />قیادة السیاّرات واستعمال الآلات<br />یمكن أن یسبّب ھذا الدواء نعاسًا واضطرابًا في الرؤیة. یجب علیك أن تكون یقظًا إذا كنت تقود سیّارة أو تستعمل آلة.<br />یحتوي سولیان على اللاكتوز والصودیوم<br />&bull; یحتوي ھذا الدواء على السكّر (اللاكتوز) الذي یتحلّل لیصبح غالاكتوز وغلوكوز. لا یُنصح باستعمالھ لدى المرضى<br />المصابین بعدم تحمّل الغالاكتوز أو بنقص لاكتاز لاب أو بمتلازمة سوء امتصاص الغلوكوز والغالاكتوز (أمراض<br />وراثیةّ نادرة).<br />&bull; إذا قال لك طبیبك إنّك تعاني من عدم تحمّل بعض أنواع السكّر، اتصل بھ قبل أخذ ھذا الدواء.<br />&bull; یحتوي ھذا الدواء على أقلّ من ملمول واحد من الصودیوم ( 23 ملغ) في القرص، أيّ أنّھ &quot;خالٍ من الصودیوم&quot;<br />أساسًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحرص دائمًا على أخذ ھذا الدواء بالتقیّد بدقةّ بتعلیمات الطبیب أو الصیدلي. إسأل الطبیب أو الصیدلي في حال الشكّ.<br />لا توقف العلاج من تلقاء ذاتك.<br />یُستعمل ھذا الدواء عن طریق الفم.<br />إبلع القرص (الأقراص) مع بعض الماء.<br />إذا أخذت كمیةّ سولیان أكثر من التي ینبغي بك أخذھا:<br />قد تشعر بنعاس أو بتسكین (تأثیر مھدّئ) أو بانخفاض ضغط الدم الشریاني أو بعوارض خارج الھرمیّة (بخاصة رجفة<br />وتیبسّ عضلي) أو یمكن أن تدخل في غیبوبة.<br />في حال حصول إحدى ھذه الحالات، یجب أن تتصل أنت شخصیًا أو أحد من محیطك بالطبیب أو بالطوارئ الطبیّة.<br />إذا نسیت أخذ سولیان:<br />لا تأخذ جرعة مضاعفة للتعویض عن الجرعة التي نسیت أخذھا، بل خذ الجرعة التالیة في وقتھا المعتاد.<br />إذا نسیت عدّة جرعات، استشر الطبیب.<br />إذا كان لدیك أسئلة أخرى حول استعمال ھذا الدواء، أطلب المزید من المعلومات من الطبیب أو الصیدليّ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدویة كلھّا، یمكن أن یسببّ ھذا الدواء تأثیرات جانبیةّ لا تصُیب المرضى كلھّم.<br />إنّ حصول تیبّس العضلات واضطرابات في الوعي مع حمى غیر مبررة في خلال فترة العلاج یتطلّب الإیقاف الفوري<br />للعلاج واستشارة طبیةّ طارئة.<br />:( تحصل التأثیرات الجانبیةّ الآتیة بصورة شائعة جدًا (أكثر من شخص واحد من أصل 10<br />&bull; رجفة، تیبسّ عضلي، تشنّجات، حركات غیر طبیعیّة، زیادة إفراز اللعاب.<br />:( تحصل التأثیرات الجانبیةّ الآتیة بصورة شائعة (من شخص واحد حتىّ 10 أشخاص من أصل 100<br />&bull; تصلبّ الرقبة، نوبات في العصب المحرّك للعین (حركات غیر طبیعیةّ في بعض عضلات العینین)، انكماش شدید في<br />الفكّ،<br />&bull; نعاس،<br />&bull; أرق، قلق، تھیّج،<br />&bull; إمساك، غثیان، تقیؤّ، جفاف الفم،<br />&bull; برودة جنسیةّ (غیاب الرغبة الجنسیّة لدى المرأة) ،<br />&bull; فرط برولاكتین الدم (كمیةّ مفرطة من البرولاكتین في الدم، الھورمون الذي یؤديّ إلى درّ الحلیب)، مما یمكن أن<br />یسببّ:<br />- لدى المرأة: توقّف العادة الشھریّة، درّ الحلیب خارج فترات الإرضاع العادیّة، أوجاعً ا في الثدیین،<br />- لدى الرجل: تورّم الثدیین وعجزً ا (اضطراب في الانتصاب).<br />&bull; زیادة في الوزن ،<br />&bull; انخفاض ضغط الدم (نقص ضغط الدم)،<br />&bull; تشوّش الرؤیة.<br />: ( تحصل التأثیرات الجانبیةّ الآتیة بصورة غیر شائعة (من شخص واحد حتىّ 10 أشخاص من أصل 1000<br />&bull; حركات غیر إرادیّة في اللسان و/أو الوجھ ،<br />&bull; اختلاجات (تقلّصات لاإرادیّة في أحد العضلات أو في عدةّ عضلات)،<br />&bull; فرط سكّر الدم (كمیّة مفرطة من السكّر في الدم)،<br />&bull; فرط ثلاثيّ غلیسیرید الدم (كمیّة مفرطة من الشحوم (الدھون الثلاثیّة) في الدم) ،<br />&bull; فرط كولیستیرول الدم (كمیةّ مفرطة من الكولیستیرول في الدم) ،<br />تباطؤ النظم القلبي،<br />&bull; زیادة انزیمات الكبد وبخاصة ناقلات الأمین،<br />&bull; إصابة أنسجة الكبد،<br />&bull; انخفاض كثافة العظام وتغ یرّ ھیكلیّتھا (ھشاشة العظام، ترقق العظام) مما یسبّب ھشاشتھا،<br />&bull; إرتكاسات تحسسیةّ،<br />&bull; تشوشّ،<br />&bull; إنسداد الأنف،<br />&bull; مرض في الرئتین (إلتھاب الرئة الناتج عن الاستنشاق) یمكن أن یظھر عبر الت ھاب وصعوبة في التنفّس وعدوى<br />وسعال (بشكل خاص بالاشتراك مع أدویة أخرى مضادة للاكتئاب تعمل على الجھاز العصبيّ المركزيّ)،<br />&bull; ارتفاع ضغط الدم الشریاني،<br />&bull; صعوبة في التبوّل،<br />&bull; قلة الكریات البیض ، قلة العدلات (راجع القسم 2، فقرة &quot;تحذیرات واحتیاطات&quot;).<br />:( تحصل التأثیرات الجانبیةّ التالیة بصورة نادرة (من شخص واحد حتىّ 10 أشخاص من أصل 10000<br />&bull; ندرة المحببات (انخفاض كمیّة الكریات البیضاء في الدم) (راجع القسم 2، فقرة &quot;تحذیرات واحتیاطات&quot;)،<br />&bull; ورم حمید في الغد ة النخامیة یمكن أن یسببّ عوارض مثل اضطرابات الرؤیة أو أوجاع الرأس ،<br />&bull; انخفاض كمیةّ الصودیوم في الدم (نقص صودیوم الدم)، متلازمة الإفراز غیر المناسب للھورمون المضاد للتبوّل ،<br />&bull; حمى غیر مبررة مترافقة مع اضطرابات عامة وعصبیةّ،<br />،( &bull; إغماء شدید (فقدان الوعي)، اضطرابات في النظم القلبي یمكن أن یسببّ الوفاة (راجع القسم 2<br />&bull; تورّ م، ألم واحمرار على مستوى الساقین. في الواقع، یمكن أن تنتقل جلطات دمویّة وریدیّة (بخاصة على مستوى<br />الساقین) عبر الأوعیة الدمویة حتىّ الرئتین وأن تتسبّب بألم في الصدر وبصعوبة في التنفّس.<br />&bull; تورّم مفاجئ في الوجھ و/أو العنق یمكن أن یسبّب صعوبة في التنفّس وتعریض حیاة المریض للخطر (وذمة وعائیّة)،<br />بقع حمراء على الجلد تسبّب الحكّة (شرى).<br />یمكن أن تحصل التأثیرات الجانبیةّ الآتیة ولكن معدّل حصولھا غیر معروف:<br />&bull; متلازمة فطام الطفل الحدیث الولادة (راجع القسم 2، فقرة &quot;الحمل&quot;)،<br />&bull; متلازمة تململ الساقین (شعور بعدم الراحة في الساقین یخفّ مؤقّتًا عن طریق الحركة وتفاقم العوارض في نھایة<br />النھار)،<br />&bull; زیادة حساسیّة الجلد عند التعرّض للشمس وللأشعة فوق البنفسجیةّ،<br />&bull; السقوط بسبب فقدان التوازن الذي قد تصاحبھ كسور.<br />الإبلاغ عن التأثیرات الجانبیةّ<br />للإبلاغ عن أي أعراض جانبیة:<br />&bull; المملكة العربیة السعودیة :<br />- المركز الوطني للتیقظ والسلامة الدوائیة<br />&bull; الرقم المُوحّد للھیئة العامّة للغذاء والدّواء: 19999<br />npc.drug@sfda.gov.sa : &bull; البرید الالكتروني<br />/ https://ade.sfda.gov.sa : &bull; الموقع الالكتروني<br />KSA_Pharmacovigilance@sanofi.com : &bull; سانوفي للتیقظ الدوائي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ ھذا الدواء بعیدًا عن نظر الأطفال ومتناولھم.<br />لا یُستعمل ھذا الدواء بعد انقضاء تاریخ الصلاحیّة المدوّن على العلبة. یشیر تاریخ انتھاء الصلاحیّة إلى الیوم الأخیر من<br />الشھر المذكور.<br />یُحفظ في درجة حرارة لا تتجاوز 25 درجة مئویّة.<br />لا ینبغي التخلّص من الأدویة عبر میاه الصرف الصحي أو النفایات المنزلیّة. أطلب من الصیدلي التخلّص من الأدویة التي<br />لم تعد تستعملھا. من شأن ھذه الإجراءات حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا یحتوي سولیان 400 ملغ،أ قراص مغلفّة قابلة للتجزئة<br />&bull; المادة الفاعلة ھي :<br />أمیسولبرید........................................................................................................................... 400 ملغ<br />في القرص المغلفّ الواحد القابل للتجزئة.<br />&bull; المكوّنات الأخرى ھي:<br />كاربوكسیمیثیل نشا الصودیودم (النوع أ)، لاكتوز وحید التمیھّ، سلولوز دقیق البلوّریةّ، ھبرومیلوز، ستیارات المغنیزیوم،<br />سیبیفیلم 752 أبیض (ھبرومیلوز، سلولوز دقیق البلوّریةّ، بولیوكسیل 40 ستیارات، ثاني أكسید التیتانیوم).<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كیف ھو شكل سولیان 400 ملغ، أقراص مغلفّة قابلة للتجزئة ومحتویات الغلاف الخارجي<br />یأتي ھذا الدواء على شكل أقرا ص قابلة للتجزئة.<br />علبة من 30 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل رخصة التسویق<br />sanofi-aventis France<br />82, Avenue Raspail<br />94250 Gentilly - France<br />المصنّع<br />Delpharm Dijon<br />6, Boulevard de l&#39;Europe<br />21800 Quetigny - France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09-2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solian 400 mg scored film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amisulpride ...................................................................................................................................... 400 mg
For one scored film-coated tablet
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scored film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of schizophrenia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology Usually:<br />&bull; if the daily dose does not exceed 400 mg, it should be administered once daily; &bull; if the daily dose exceeds 400 mg, it should be administered as two divided doses.<br />Acute psychotic episodes<br />It is possible to start via the IM route for a few days, at a maximum dose of 400 mg/day, switching thereafter to oral treatment.<br />Doses between 400 mg/day and 800 mg/day are recommended for oral administration. The maximum daily dose should never exceed 1.200 mg. Given that there has been no large-scale safety assessment of doses higher than 1.200 mg/day, these doses should not be used.<br />The dosage should then be maintained or adjusted depending on the patient&#39;s individual response.<br />In all cases, the maintenance treatment should be established individually with the minimum effective dose.<br />Predominantly negative episodes<br />Doses between 50 mg/day and 300 mg/day are recommended. Doses should be adjusted individually. The optimum dose is about 100 mg/day.<br />Children and adolescents<br />The efficacy and safety of amisulpride from puberty to the age of 18 years have not been established: there are limited data available on the use of amisulpride in adolescents with schizophrenia. Therefore, the use of amisulpride from puberty to the age of 18 years is not recommended. Amisulpride is contraindicated in children under 15 years of age, since the safety of the drug has not been established (see section 4.3).<br />Elderly patients<br />The safety of amisulpride has been assessed in a limited number of elderly subjects. The medicinal product should be used with particular caution in this patient population due to the risk of hypotension and sedation. Dose reduction may also be required in patients with kidney failure (see section 4.4).<br />Renal impairment<br />Amisulpride is eliminated by the renal route. In renal impairment, the dose should be reduced to half in patients with creatinine clearance (CRCL) between 30-60 mL/min and to a third in patients with CRCL between 10-30 mL/min.<br />As there is no experience in patients with severe renal impairment (CRCL &lt; 10 mL/min) particular care is recommended in these patients (see section 4.4).<br />Hepatic impairment<br />Since amisulpride is poorly metabolised, a dose reduction is not necessary in patients with liver failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product MUST NOT BE USED in the following situations:
• Hypersensitivity to amisulpride or any of the excipients listed in section 6.1
• Serious hypertensive events have been reported in patients with pheochromocytoma using antidopaminergic drugs, including some benzamides. This medicinal product should therefore not be prescribed to known or suspected pheochromocytoma carriers
• Children under 15 years of age, because no clinical data are available
• Known or suspected prolactin-dependent tumours, e.g. pituitary gland prolactinomas and breast cancer (see sections 4.4 and 4.8)
• In combination with:
o non-antiparkinsonian dopamine agonists (cabergoline, quinagolide) o citalopram, escitalopram, domperidone, hydroxyzine, piperaquine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potentially fatal neuroleptic malignant syndrome<br />As with other neuroleptics, neuroleptic malignant syndrome, a potentially fatal complication characterised by hyperthermia, muscle rigidity and autonomic instability, consciousness disturbances and elevated creatine phosphokinase (CPK), may occur. In the event of hyperthermia, particularly with high daily doses, all antipsychotic drugs including amisulpride should be discontinued.<br />Prolongation of the QT interval<br />Amisulpride induces a dose-dependent prolongation of the QT interval. This effect, known to potentiate the risk of serious ventricular arrhythmias, particularly torsades de pointes, is worsened in patients with bradycardia, hypokalaemia, or congenital or acquired prolonged QT interval (use in combination with a drug increasing the QTc interval) (see section 4.8).<br />Prior to administration and depending on the patient&#39;s clinical status, it is necessary to rule out any risk factors for arrhythmias, such as:<br />&bull; bradycardia less than 55 bpm<br />&bull; hypokalaemia<br />&bull; congenital prolongation of the QT interval<br />&bull; ongoing treatment with a medication likely to produce pronounced bradycardia (&lt;55 bpm), hypokalaemia, decreased intracardiac conduction or prolongation of the QTc interval (see sections 4.3 and 4.5).<br />An ECG should be performed as part of the initial assessment of patients requiring long-term treatment with a neuroleptic.<br />Stroke<br />In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase in the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs, or other populations of patients cannot be excluded. This medicinal product should be used with caution in patients with stroke risk factors.<br />Elderly patients with dementia<br />There is an increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs.<br />Analyses of seventeen placebo-controlled trials (mean duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of mortality in drug-treated patients of between 1.6 to 1.7 times the risk of mortality in placebo-treated patients.<br />Over the course of a typical 10-week treatment period, the mortality rate in drug-treated patients was approximately 4.5%, compared to approximately 2.6% in the placebo group.<br />Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature.<br />Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.<br />It is unclear how much the antipsychotic drug and patient characteristics contribute to the increase in mortality found in the epidemiological studies.<br />Venous thromboembolism<br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotic drugs often have acquired risk factors for VTE, any potential risk factors for VTE must be identified before and during treatment with Solian and preventive measures should be taken if needed (see section 4.8).<br />Hyperglycaemia/Metabolic syndrome<br />Cases of hyperglycaemia or glucose intolerance and onset or exacerbation of diabetes have been reported in patients treated with certain atypical antipsychotic drugs, including amisulpride (see section 4.8).<br />Clinical and laboratory monitoring should be performed in patients receiving treatment with Solian in compliance with current recommendations. Particular caution should be exercised in patients with diabetes mellitus or with risk factors for diabetes.<br />Seizures<br />Amisulpride may lower the seizure threshold. Therefore, patients with a history of seizures should be closely monitored during treatment with Solian.<br />Special populations<br />As amisulpride is eliminated by the renal route, the dose should be decreased in patients with renal failure or another treatment may be considered (see section 4.2). There are no data concerning patients with serious renal failure (see section 4.2).<br />Amisulpride, like all antipsychotics, should be used with particular caution in elderly patients due to the potential risk of sedation and hypotension. A dose reduction may also be required in elderly patients with renal failure (see section 4.2).<br />As with other antidopaminergic agents, caution should be exercised when administering amisulpride in patients with Parkinson&#39;s disease since it may cause worsening of the disease. Amisulpride should be used only if neuroleptic treatment cannot be avoided.<br />Withdrawal syndrome<br />Withdrawal symptoms including nausea, vomiting and insomnia have been described following sudden discontinuation of high doses of antipsychotics. Recurrence of psychotic symptoms may also be observed and involuntary movement disorders (such as akathisia, dystonia and dyskinesia) have been reported with amisulpride. Therefore, gradual withdrawal of amisulpride is advisable.<br />Hyperprolactinemia<br />Amisulpride may increase prolactin levels (see section 4.8). Patients with a history of hyperprolactinemia or of a potentially prolactin-dependent tumour should be closely monitored during amisulpride treatment (see section 4.3).<br />Benign pituitary tumour<br />Amisulpride may increase prolactin levels. Cases of benign pituitary tumours such as prolactinoma have been observed during amisulpride therapy (see section 4.8). In case of very high levels of prolactin or clinical signs of pituitary tumour (such as visual field defect and headache), pituitary imaging should be performed. If the diagnosis of pituitary tumour is confirmed, amisulpride treatment must be stopped (see section 4.3).<br />Hepatotoxicity<br />Severe hepatotoxicity has been reported with the use of amisulpride. Patients should be informed that any signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or jaundice must be reported to a doctor immediately. Investigations including a clinical examination and liver function tests must be carried out immediately (see section 4.8).<br />Other<br />Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics, including Solian. Unexplained infections or fever may be evidence of leukopenia (see section 4.8), and require immediate blood tests.<br />Use of this drug is not recommended in combination with alcohol, dopaminergic antiparkinsonian drugs, antiparasitics likely to induce torsades de pointes, methadone, levodopa and other neuroleptics and drugs likely to induce torsades de pointes, sodium oxybate and hydroxychloroquine (see section 4.5).<br />Warning related to the excipients<br />This medicinal product contains lactose. It is not recommended in patients with galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>r arrhythmias, particularly torsades de pointes.<br />When coadministering these agents, clinical and ECG monitoring are required.<br />Combinations to be taken into account<br />+ Other sedative drugs<br />The central nervous depressant effect is potentiated.<br />Impaired alertness may make driving vehicles and using machines dangerous.<br />+ Orlistat<br />There is a risk of treatment failure when the drug is coadministered with orlistat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>+ Sedative drugs<br />Many drugs or substances can have additive depressant effects on the central nervous system and contribute to decreased alertness. This must be taken into account for patients using amisulpride. These drugs/substances include morphine derivatives (analgesics, cough suppressants and replacement therapies), neuroleptics, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines (e.g. meprobamate), hypnotics, sedative antidepressants (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine), sedative H1 antihistamines, centrally acting antihypertensive agents, baclofen and thalidomide.<br />+ Medications likely to induce torsades de pointes<br />This serious cardiac rhythm disorder can be caused by a number of antiarrhythmic and non-antiarrhythmic drugs. Hypokalaemia (see Potassium-depleting agents) is a promoting factor, as is bradycardia (see Bradycardia-inducing drugs) or pre-existing congenital or acquired QT interval prolongation.<br />Medicines likely to cause this adverse effect include class Ia and III antiarrhythmic agents and certain neuroleptics.<br />Other agents not belonging to these classes are also involved.<br />For dolasetron, erythromycin, spiramycin and vincamine, only intravenously administered forms are concerned by this interaction.<br />Coadministration of two torsadogenic drugs is generally contraindicated.<br />However, some of these torsadogenic drugs are exceptions to this as they are considered essential. In this case, coadministration is simply not recommended. These torsadogenic drugs include methadone, hydroxychloroquine, antiparasitic agents (chloroquine, halofantrine, lumefantrine, pentamidine), neuroleptics.<br />However, citalopram, escitalopram, domperidone, hydroxyzine and piperaquine are not among these exceptions, and are therefore contraindicated when coadministered with all torsadogenic drugs.<br />Contraindicated combinations<br />+ Non-antiparkinsonian dopamine agonists (cabergoline, quinagolide) There is mutual antagonism between dopamine agonists and neuroleptics.<br />+ Citalopram, escitalopram, domperidone, hydroxyzine, piperaquine<br />There is an increased risk of ventricular arrhythmias, especially torsades de pointes.<br />Inadvisable combinations<br />+ Antiparasitics likely to induce torsades de pointes (chloroquine, halofantrine, lumefantrine, pentamidine)<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />If possible, one of the two treatments should be discontinued.<br />If coadministration cannot be avoided, a preliminary QT examination should be carried out and ECG monitoring performed.<br />+ Antiparkinsonian dopamine agonists (amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramipexole, rasagiline, ropinirole, rotigotine, selegiline, tolcapone)<br />There is mutual antagonism between dopamine agonists and neuroleptics.<br />Dopamine agonists can cause or worsen psychotic disorders. If treatment with neuroleptics is required in patients with Parkinson&#39;s disease treated with dopamine agonists, these dopamine agents should be tapered off gradually (sudden discontinuation exposes the patient to a risk of &ldquo;neuroleptic malignant syndrome&rdquo;).<br />+ Other medications likely to induce torsades de pointes: class Ia antiarrhythmic agents (quinidine, hydroquinidine, disopyramide) and class III antiarrhythmics (amiodarone, dronedarone, sotalol, dofetilide, ibutilide), and other drugs such as arsenic compounds, diphemanil, dolasetron IV, erythromycin IV, levofloxacin, mequitazine, mizolastine, prucalopride, vincamine IV, moxifloxacin, spiramycin IV, toremifene, vandetanib There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />+ Other neuroleptics which could induce torsades de pointes (chlorpromazine, cyamemazine, droperidol, flupenthixol, fluphenazine, haloperidol, levomepromazine, pimozide, pipamperone, pipotiazine, sulpiride, sultopride, tiapride, zuclopenthixol)<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />+ Alcohol (beverage or excipient)<br />Alcohol potentiates the sedative effects induced by this type of drug.<br />Impaired alertness may make driving vehicles and using machines dangerous.<br />Consumption of alcoholic beverages and medicinal products containing alcohol should be avoided.<br />+ Levodopa<br />There is mutual antagonism between levodopa and neuroleptics.<br />In patients with Parkinson&#39;s disease, minimum effective doses of each of these drugs should be used. + Methadone<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />+ Sodium oxybate<br />The central nervous depressant effect is potentiated. Impaired alertness may make driving vehicles and using machines dangerous. + Hydroxychloroquine<br />There is an increased risk of ventricular arrhythmias, especially torsades de pointes.<br />Combinations requiring precautions for use<br />+ Anagrelide<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />When coadministering these agents, clinical and ECG monitoring are required.<br />+ Azithromycin, ciprofloxacin, clarithromycin, levofloxacin, norfloxacin, roxithromycin There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />When coadministering these agents, clinical and ECG monitoring are required.<br />+ Beta-blockers in heart failure (bisoprolol, carvedilol, metoprolol, nebivolol)<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />In addition, there is a vasodilator effect and risk of hypotension, particularly postural (additive effect). Clinical and ECG monitoring are required.<br />+ Bradycardia-inducing drugs (in particular class IA antiarrhythmics, beta-blockers, certain class III antiarrhythmics, certain calcium channel blockers, digitalis glycosides, pilocarpine, anticholinesterases)<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />Clinical and ECG monitoring are required.<br />+ Potassium-depleting agents (potassium-depleting diuretics, alone or in combination, stimulant laxatives, glucocorticoids, tetracosactides and amphotericin B IV)<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />Any existing hypokalaemia should be corrected before administration, and clinical, electrolyte and ECG monitoring implemented.<br />+ Lithium<br />There is a risk of neuropsychiatric signs suggestive of neuroleptic malignant syndrome or lithium poisoning. Regular clinical and laboratory monitoring are required, particularly at the start of coadministration.<br />+ Ondansetron<br />There is an increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />When coadministering these agents, clinical and ECG monitoring are required.<br />Combinations to be taken into account<br />+ Other sedative drugs<br />The central nervous depressant effect is potentiated.<br />Impaired alertness may make driving vehicles and using machines dangerous.<br />+ Orlistat<br />There is a risk of treatment failure when the drug is coadministered with orlistat.<br />4.6. Fertility, pregnancy and lactation<br />Pregnancy<br />Available data on the use of amisulpride in pregnant women are limited. Therefore, the safety of amisulpride during human pregnancy has not been established.<br />Amisulpride crosses the placenta.<br />Animal studies have shown reproductive toxicity (see section 5.3).<br />The use of amisulpride is not recommended during pregnancy and in women of child-bearing potential not using effective contraception, unless the benefits of such treatment outweigh the potential risks.<br />Neonates exposed to antipsychotics, including Solian, during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery (see section 4.8). There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress or feeding disorder. Consequently, newborns should be monitored carefully.<br />Breastfeeding<br />A significant amount of amisulpride is excreted in breast milk. In some cases the amount exceeds the accepted value of 10% of the mother&#39;s weight-adjusted dose; however, blood concentrations in breast-fed infants have not been evaluated. There are inadequate data on the effects of amisulpride in neonates/infants.<br />The benefit of breast-feeding for the infant should be weighed against the benefit of amisulpride treatment when deciding to stop breast-feeding or to not take amisulpride.<br />Fertility<br />A decrease in fertility linked to the pharmacological effects of the drug (prolactin-mediated effect) was observed in treated animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients, especially those who drive and use machines, should be warned of the risk of drowsiness or blurred vision associated with the use of this drug (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects have been grouped by frequency using the following convention: very common<br />&ge;1/10; common &ge;1/100 to &lt;1/10; uncommon &ge;1/1 000 to &lt;1/100; rare &ge;1/10 000 to &lt;1/1 000; very rare &lt;1/10 000, not known (cannot be estimated from the available data).<br />Blood and lymphatic system disorders<br />Uncommon<br />Leukopenia, neutropenia (see section 4.4).<br />Rare<br />Agranulocytosis (see section 4.4).<br />Immune system disorders<br />Uncommon<br />Allergic reactions.<br />Endocrine disorders<br />Common<br />Increase in plasma prolactin levels which is reversible on treatment discontinuation. This may result in the following clinical signs and symptoms: galactorrhoea, amenorrhoea, gynecomastia, breast pain, erectile dysfunction.<br />Rare<br />Benign pituitary tumour such as prolactinoma (see sections 4.3 and 4.4)<br />Metabolism and nutrition disorders<br />Uncommon<br />Hyperglycaemia (see section 4.4), hypertriglyceridemia and hypercholesterolaemia.<br />Rare<br />Hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH).<br />Psychiatric disorders<br />Common<br />Insomnia, anxiety, agitation, frigidity.<br />Uncommon<br />Confusion.<br />Nervous system disorders<br />Very common<br />Extrapyramidal symptoms may occur: tremor, hypertonia, hypersalivation, akathisia, hypokinesia, dyskinesia. These symptoms are generally moderate with optimal doses and partially reversible without discontinuation of Solian upon administration of antiparkinsonian medication.<br />The incidence of extrapyramidal symptoms, which are dose-related, remains very low in the treatment of patients with predominantly negative symptoms with doses of 50-300 mg/day.</p><p>Common<br />Acute dystonia (spasm torticollis, oculogyric crises, trismus, etc.) may appear. This is reversible with administration of an anticholinergic antiparkinsonian agent. Discontinuation of amisulpride treatment is not required.<br />Somnolence.<br />Uncommon<br />Tardive dyskinesia, characterised by involuntary movements of the tongue and/or face, has been reported, usually after long-term administration.<br />Anticholinergic antiparkinsonians are ineffective or may induce aggravation of the symptoms.<br />Seizures. Rare<br />Neuroleptic malignant syndrome, which is a potentially fatal complication (see section 4.4).<br />Not known<br />Restless legs syndrome.<br />Eye disorders<br />Common<br />Blurred vision (see section 4.7).<br />Cardiac disorders<br />Uncommon<br />Bradycardia.<br />Rare<br />QT interval prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, which may result in ventricular fibrillation or cardiac arrest, sudden death (see section 4.4).<br />Vascular disorders<br />Common<br />Hypotension.<br />Uncommon<br />Increase in blood pressure.<br />Rare<br />Cases of venous thromboembolism, including cases of pulmonary embolism, sometimes fatal, and deep vein thrombosis, have been reported with antipsychotic drugs (see section 4.4).<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon<br />Nasal congestion, aspiration pneumonia (mainly in association with other antipsychotics and CNS depressants).<br />Gastrointestinal disorders<br />Common<br />Constipation, nausea, vomiting, dry mouth.<br />Hepatobiliary disorders<br />Uncommon<br />Hepatocellular injury.<br />Skin and subcutaneous tissue disorders<br />Rare<br />Angioedema, urticaria.<br />Not known<br />Photosensitivity reaction.<br />Musculoskeletal and systemic disorders<br />Uncommon<br />Osteopenia, osteoporosis.<br />Renal and urinary disorders<br />Uncommon<br />Urinary retention.<br />Injury, poisoning and procedural complications<br />Not known<br />Falls resulting from adverse effects compromising balance<br />Pregnancy, puerperium and perinatal conditions<br />Not known<br />Neonatal drug withdrawal syndrome (see section 4.6).<br />Investigations<br />Common<br />Weight gain.<br />Uncommon<br />Elevations of hepatic enzymes, mainly transaminases.<br />Reporting of suspected adverse reactions<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To date, available data on acute amisulpride overdose are limited. The signs and symptoms reported generally result from exaggeration of the pharmacological effects of the medicinal product, clinically presenting as: drowsiness, sedation, coma, hypotension and extrapyramidal symptoms. Fatal outcomes have been reported, mainly in combination with other antipsychotic agents.<br />There is no known specific antidote to amisulpride. In the event of acute overdose, use of this drug in combination with other medicinal products should be considered and appropriate measures taken:<br />&bull; Close monitoring of vital functions.<br />&bull; Cardiac monitoring (risk of prolongation of the QT interval) until the patient recovers.<br />&bull; If severe extrapyramidal symptoms occur, anticholinergic agents should be administered.<br />&bull; Since amisulpride is poorly dialysed, haemodialysis is of limited use to eliminate the drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ANTIPSYCHOTICS, ATC code: N05AL05<br />Amisulpride is an antipsychotic drug, which belongs to the class of substituted benzamides.<br />The pharmacodynamic profile of the drug is characterised by a selective and predominant affinity for dopamine D2 and D3 receptors in the limbic system. Amisulpride has no affinity for serotonin receptors, or other neuroreceptors such as histamine, cholinergic and adrenergic receptors.<br />In animal studies, at high doses, amisulpride preferentially blocks the dopaminergic neurons of the mesolimbic system compared to those in the striatal system. This specific affinity could explain the predominant antipsychotic effects of amisulpride compared with its extrapyramidal effects.<br />At low doses, amisulpride preferentially blocks the presynaptic D2/D3 dopaminergic receptors, which could explain its effects on negative symptoms.<br />In a controlled, double-blind study versus haloperidol conducted in 191 patients with acute schizophrenia, improvement of secondary negative symptoms was significantly greater with amisulpride compared to haloperidol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In humans, amisulpride shows two absorption peaks: the first is achieved rapidly, one hour post-dose, and the second between 3 and 4 hours after administration.<br />Corresponding plasma concentrations after administration of a 50 mg dose are 39 &plusmn; 3 ng/mL (one hour post-dose) and 54 &plusmn; 4 ng/mL (between 3 and 4 hours post-dose).<br />The volume of distribution is 5.8 L/kg; plasma protein binding is low (16%) and no drug interactions related to plasma protein binding are suspected. Absolute bioavailability is 48%.<br />Amisulpride is poorly metabolised: two inactive metabolites have been identified and account for approximately 4% of the total amount of drug eliminated.<br />There is no accumulation of amisulpride, and its pharmacokinetics remain unchanged after the administration of repeated doses.<br />The elimination half-life is approximately 12 hours after an oral dose.<br />Amisulpride is eliminated unchanged in the urine. 50% of an intravenous dose is excreted via the urine, of which 90% is eliminated in the first 24 hours.<br />Renal clearance is approximately 330 mL/min.<br />A carbohydrate-rich meal significantly decreases the AUC, Tmax and Cmax of amisulpride but no changes are seen after a high-fat meal. The relevance of these findings in patients receiving amisulpride treatment is not known.<br />Liver failure<br />Since amisulpride is poorly metabolised, a dose reduction is not necessary in patients with liver failure. Kidney failure<br />The elimination half-life is unchanged in patients with kidney failure while total clearance is reduced by a factor of 2.5 to 3.<br />The AUC of amisulpride in patients with mild kidney failure is increased two-fold and almost ten-fold in patients with moderate kidney failure.<br />Experience is limited, however, and there are no available data on doses higher than 50 mg.<br />Amisulpride is poorly dialysable.<br />Elderly subjects<br />The pharmacokinetic data available for subjects aged over 65 years show that a 10-30% increase occurs in Cmax, T1/2 and AUC after a single dose of 50 mg.<br />No data are available after repeated dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of amisulpride is determined by the pharmacological effects of the compound. Repeated-dose toxicity studies showed no target organ impairment. In animal studies, amisulpride had an effect on foetal growth and development at doses corresponding to an equivalent human dose of 2.000 mg/day and over in patients weighing 50 kg. There is no evidence that&nbsp;amisulpride has teratogenic potential. No studies have been carried out on the effect of amisulpride on the behaviour of the offspring.<br />Carcinogenesis studies have demonstrated hormone-dependent tumours in rodents. These are not clinically relevant in humans.<br />Decreased fertility related to the pharmacological properties of the product (prolactin-mediated effects) was observed in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium starch glycolate (Type A), lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate.<br />Film-coating: white Sepifilm 752 (hypromellose, microcrystalline cellulose, polyoxyl 40 stearate, titanium dioxide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30, 80, 100 or 150 tablets in (PVC/aluminium) blisters.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI-AVENTIS FRANCE
82 AVENUE RASPAIL
94250 GENTILLY, FRANCE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09-2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>